Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.
Drugs Today (Barc)
; 51(8): 457-68, 2015 Aug.
Article
in En
| MEDLINE
| ID: mdl-26380384
ABSTRACT
Peyronie's disease (PD) is defined as the abnormal accumulation of connective tissue in the tunica albuginea of the penis, and is an ongoing physical and psychological challenge for thousands of Americans. In vitro studies in the 1950s uncovered the potential of collagenase Clostridium histolyticum (CCH) to disrupt the collagen-containing plaques in PD, and opened the door to more in-depth clinical trials. Results indicated that with multiple dosage cycles followed by plaque modeling, penile curvature can be corrected, on average, in up to 35% of cases, with the majority of patients achieving ≥ 25% improvement in penile curvature. Most studies also indicated an improvement in patient-reported symptoms from the Peyronie's Disease Questionnaire. Adverse events from treatment with CCH included penile bruising, pain and edema, but most were mild to moderate in severity and usually resolved without intervention, suggesting that CCH is an effective and safe treatment for PD.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Penile Induration
/
Microbial Collagenase
Type of study:
Qualitative_research
Limits:
Humans
/
Male
Language:
En
Journal:
Drugs Today (Barc)
Journal subject:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Year:
2015
Document type:
Article
Affiliation country:
United States